草酸艾司西酞普兰联合阿戈美拉汀治疗焦虑性抑郁症的疗效和不良反应分析

Efficacy and adverse reactions of escitalopram oxalate combined with agomelatine in the treatment of anxiety depression

目的 探究与分析草酸艾司西酞普兰联合阿戈美拉汀治疗焦虑性抑郁症的疗效和不良反应。方法 采取随机数字表法对2021年4月~2022年5月收治的60例焦虑性抑郁症患者分组,各30例,对照组给予口服草酸艾司西酞普兰治疗,观察组加用阿戈美拉汀治疗,对比两组患者临床疗效、治疗前后汉密尔顿焦虑量表评分(HAMA)、汉密尔顿抑郁量表(HAMD)片评分、血清脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)及去甲肾上腺素(NE)水平,同时观察用药期间不良反应。结果 观察组与对照组相比临床总有效率较高,观察组治疗后与对照组治疗后相比HAMA评分、HAMD评分均较低,血清BDNF、5-HT及NE水平均较高,差异有统计学意义(P <0.05)。两组治疗期间不良反应相比,差异无统计学意义(P> 0.05)。结论 草酸艾司西酞普兰联合阿戈美拉汀治疗焦虑性抑郁症可更好地缓解相关症状及体征,改善焦虑及抑郁情绪,同时可促进调节血清BDNF、5-HT及NE水平,且在治疗期间尚未增加不良反应,安全性较高。

Objective To explore and analyze the efficacy and adverse reactions of escitalopram oxalate combined with agomelatine in the treatment of anxiety depression. Methods A total of 60 patients with anxiety depression admitted to our hospital from April 2021 to May 2022 were selected and divided into three groups according to the random number table method, with 30 cases in each group. The control group was treated with oral escitalopram oxalate, while the observation group was treated with agomelatine. The clinical efficacy, Hamilton anxiety scale(HAMA) score, Hamilton Depression Scale(HAMD) score, serum levels of brain-derived neurotrophic factor(BDNF), 5-hydroxytryptamine(5-HT) and norepinephrine(NE) before and after treatment were compared between the two groups, and the adverse reactions during treatment were observed. Results The total effective rate of the observation group was higher than that of the control group,Compared with the control group after treatment, the HAMA score and HAMD score of the observation group were lower, and the serum BDNF, 5-HT and NE levels were higher, and the differences were statistically significant(P < 0.05). There was no significant difference in adverse reactions between the two groups during treatment(P > 0.05). Conclusion Escitalopram oxalate combined with agomelatine in the treatment of anxiety depression can better relieve the related symptoms and signs, improve anxiety and depression, and promote the regulation of serum BDNF, 5-HT and NE levels, and has no increased adverse reactions during treatment, with high safety.